Literature DB >> 19707242

Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.

Massimo Di Maio1, Bruno Daniele, Francesco Perrone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19707242     DOI： 10.1038/nrclinonc.2009.114

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

Review 2.  Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Authors:  Robert C Kane; Ann T Farrell; Rajanikanth Madabushi; Brian Booth; Somesh Chattopadhyay; Rajeshwari Sridhara; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2009-01-14

3.  Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.

Authors:  Matthias Pinter; Wolfgang Sieghart; Ivo Graziadei; Wolfgang Vogel; Andreas Maieron; Robert Königsberg; Adalbert Weissmann; Gabriela Kornek; Christina Plank; Markus Peck-Radosavljevic
Journal:  Oncologist       Date:  2009-01-14

4.  Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.

Authors:  Andrew X Zhu; Jeffrey W Clark
Journal:  Oncologist       Date:  2009-01-15

5.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

Review 6.  Design and endpoints of clinical trials in hepatocellular carcinoma.

Authors:  Josep M Llovet; Adrian M Di Bisceglie; Jordi Bruix; Barnett S Kramer; Riccardo Lencioni; Andrew X Zhu; Morris Sherman; Myron Schwartz; Michael Lotze; Jayant Talwalkar; Gregory J Gores
Journal:  J Natl Cancer Inst       Date:  2008-05-13       Impact factor: 13.506

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

Authors:  Marcus Alexander Wörns; Arndt Weinmann; Kerstin Pfingst; Carla Schulte-Sasse; Claudia-Martina Messow; Henning Schulze-Bergkamen; Andreas Teufel; Marcus Schuchmann; Stephan Kanzler; Christoph Düber; Gerd Otto; Peter Robert Galle
Journal:  J Clin Gastroenterol       Date:  2009 May-Jun       Impact factor: 3.062

9.  Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.

Authors:  Antonius A Miller; Daryl J Murry; Kouros Owzar; Donna R Hollis; Erin B Kennedy; Ghassan Abou-Alfa; Apurva Desai; Jimmy Hwang; Miguel A Villalona-Calero; E Claire Dees; Lionel D Lewis; Marwan G Fakih; Martin J Edelman; Fred Millard; Richard C Frank; Raymond J Hohl; Mark J Ratain
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
  9 in total
  13 in total

Review 1.  Methodological assessment of HCC literature.

Authors:  G Daniele; N Costa; V Lorusso; J Costa-Maia; I Pache; M Pirisi
Journal:  Ann Oncol       Date:  2013-04       Impact factor: 32.976

2.  Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.

Authors:  Alok R Singh; Shweta Joshi; Adam M Burgoyne; Jason K Sicklick; Sadakatsu Ikeda; Yuko Kono; Joseph R Garlich; Guillermo A Morales; Donald L Durden
Journal:  Mol Cancer Ther       Date:  2016-08-05       Impact factor: 6.261

3.  Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.

Authors:  Esteban Rodrigo Imedio; Roberto Díaz Beveridge; Jorge Aparicio Urtasun; Gema Bruixola Campos; David Lorente Estellés; María Fonfría Esparcia; Javier Caballero Daroqui; Ángel Segura Huerta; Alejandra Giménez Ortiz; Joaquin Montalar Salcedo
Journal:  Med Oncol       Date:  2014-04-17       Impact factor: 3.064

4.  Safety and Efficacy of Physical Thermal Ablation Combined Sorafenib for Hepatocellular Carcinoma: A Meta-analysis.

Authors:  Mengdi Jin; Qiong Yu; Yahui Liu; Weiling Xu; Xueqi Fu; Bai Ji
Journal:  J Clin Transl Hepatol       Date:  2021-03-08

5.  Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.

Authors:  Anne Helene Køstner; Morten Sorensen; René Krøjgaard Olesen; Henning Grønbæk; Ulrik Lassen; Morten Ladekarl
Journal:  ScientificWorldJournal       Date:  2013-01-29

6.  SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.

Authors:  Jung-Chen Su; Ping-Hui Tseng; Szu-Hsien Wu; Cheng-Yi Hsu; Wei-Tien Tai; Yong-Shi Li; I-Ting Chen; Chun-Yu Liu; Kuen-Feng Chen; Chung-Wai Shiau
Journal:  Neoplasia       Date:  2014-07-18       Impact factor: 5.715

7.  Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.

Authors:  Guangchao Cao; Xiaoyun Li; Chao Qin; Jie Li
Journal:  Med Sci Monit       Date:  2015-10-18

8.  Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.

Authors:  Jianhua Liu; Yahui Liu; Lingyu Meng; Kai Liu; Bai Ji
Journal:  Oncol Rep       Date:  2017-06-14       Impact factor: 3.906

9.  Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.

Authors:  Zhi-Yuan Chen; Ming Shi; Li-Xia Peng; Wei Wei; Xin-Jian Li; Zhi-Xing Guo; Shu-Hong Li; Chong Zhong; Chao-Nan Qian; Rong-Ping Guo
Journal:  J Transl Med       Date:  2012-12-10       Impact factor: 5.531

10.  Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials.

Authors:  Massimo Di Maio; Gennaro Daniele; Maria Carmela Piccirillo; Pasqualina Giordano; Giuseppe Signoriello; Bruno Daniele; Francesco Perrone
Journal:  Cancers (Basel)       Date:  2012-06-05       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.